Workshop Invitation:
Novel in vitro cell models for improved compound & target research
Kathrin Schmitt, SIRION Biotech GmbH, Munich, Germany
Jens Kelm, InSphero AG, Zurich, Switzerland
Christian Thirion, SIRION Biotech GmbH, Munich, Germany
A growing list of publications addresses the research community’s interest in improved cell models with higher predictivity. These are critical for an effective compound development or new drug candidates. This "After-Work" seminar will offer you an overview of novel in vitro cell models for improved compound & target research from 2D to 3D cell culture.
SIRION BIOTECH specializes in viral vector platforms and provides sophisticated cell models. This enables much improved target identification and compound screening in the drug, the food and cosmetic industries. It allows for much better chances to succeed with primary cell immortalizations. SIRION BIOTECH is able to construct adenovirus serotype vectors serving as the basis for novel future vaccines with much improved immunity.
Date: 06 March 2012 15:00-18:00 at the IZB Conference Room Kubus 1 + 2
15:00 - 15:30 Welcome Reception
15:30 - 16:15 Improved cell based models for the pharma and biotech industries - combining viral vector and cell technology - Kathrin Schmitt, Sirion Biotech GmbH
16:30 - 17:15 Compound de-risking with 3D-cell-culture sytems - Jens Kelm, In Sphero AG
17:30 - 18:15 Viral vectors and cellular models for drug research - from 2D to 3D - Christian Thirion, Sirion Biotech GmbH
18:15 - 19:00 Networking with Fingerfood & Drinks
Free Registration:
Attendance is limited, therefore, please e-mail (info@sirion-biotech.com) or fax (+49 89 700 961 99 8) before 01 March 2012. Please provide Name, Function, Company / Institute, Address, eMail – Thank you very much! Or visit our Contacts Page on our website.
For questions please contact: Peter Frost: Phone: +49 89 700 961 99 16,Fax: +49 89 700 961 99 ,eMail: frost@sirion-biotech.com |
